AntiviralPK
Meeting category
Date(s)
20 Sep 2021 - 22 Sep 2021
Important dates
Same Day Registration Fees Apply
20 September - 13 October 2021
Meeting type
Virtual Meeting
Organizer
Platinum Level Sponsor
Sponsor logos
Gilead Sciences

International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021

Related Enduring Materials

Enduring Materials
Enduring Materials
Day 1 - Monday, 20 September 2021
John Gerber Memorial Lecture -
Transporters Expression in Brain and Other Tissues
Reina Bendayan, Pharm.D.
University of Toronto, Canada
Transporter-Mediated Drug-Drug Interactions: Challenges with Probe Drugs and Interpretation
Kellie Schoolar Reynolds, PharmD
Center for Drug Evaluation and Research, FDA, United States
Clinical Pharmacology of COVID-19 -
Small Molecules and mAbs as Antiviral Therapy for COVID-19
Daniel Kuritzkes, MD
Brigham and Women's Hospital / Harvard Medical School, United States
Tackling the Immune System in Patients With COVID-19
Andrea Calcagno, MD, DTM&H
University of Turin, Italy
Pharmacological Management of Complex Patients
Margherita Bracchi, MD
Chelsea and Westminster Hospital, United Kingdom
Abstract-Driven Session -
Abstract Presentations
Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, open-label, dose-escalating, randomised controlled study
#1 - Saye Khoo, PharmD | University of Liverpool, United Kingdom
An open label, adaptive, phase 1 trial of high-dose oral nitazoxanide in healthy volunteers: an antiviral candidate for treatment of COVID-19
#2 - Lauren Walker, MBCHB PHD | University Of Liverpool, United Kingdom
Drug-Drug Interactions in Hospitalized COVID-19 Patients Receiving Investigational Drugs (CATCO-DDI)
#3 - Nancy Sheehan, PharmD, MSc | McGill University Health Centre, Canada
Abstract-Driven Session on DDIs -
Abstract Presentations followed by a Discussion
Absence of drug-drug interaction between γ-hydroxybutyric acid (GHB) and cobicistat
#4 - José Moltó, MD, PhD | Hospital Universitari Germans Trias i Pujol, Spain
Pharmacokinetics sub-study of twice daily dolutegravir with once-daily ritonavir boosted darunavir in treatment-naïve individuals enrolled in NOVA study
#5 - Leena Zino, MSc | Radboudumc, the Netherlands
A Phase 3, Open-label, Dose Escalation study to determine the pharmacokinetics of Atazanavir administered with RIfampicin to HIV positive adults on sEcond-line ART regimen with suppressed HIV-1 viral load (DERIVE): Scheduled Interim Analysis
#6 - Kamunkhwala Gausi | University of Liverpool, United Kingdom
Day 2 - Tuesday, 21 September 2021
Innovative Approaches for Antiviral Pharmacology -
Applications and Challenges of ML and AI for Pharmacogenomics
Dennis Wang, BSc, MPhil, PhD, FHEA
The University of Sheffield and Singapore Institute for Clinical Sciences, United Kingdom
Predictive Modelling for Drug Development and Clinical Scenarios
Marco Siccardi, PhD
University of Liverpool, United Kingdom
Imaging Drug Disposition in Tissues for PK/PD
Elias Rosen, Ph.D.
University of North Carolina, Chapel Hill, United States
Debate: TAF versus TDF -
Short Presentations followed by a Debate
Giovanni Di Perri, MD, PhD
University of Turin, Italy
Jose Castillo-Mancilla, MD
University of Colorado School of Medicine, United States
Abstract-Driven Session -
Abstract Presentations
The Spatial Relationship between Antiretrovirals and Cell-Associated RT-SHIV RNA in the Spleens of Nonhuman Primates using Quantitative Imaging Analysis
#7 - Aaron Devanathan, PharmD | University of North Carolina at Chapel Hill, United States
Low-level viremia is associated with lower cumulative adherence to antiretroviral therapy in persons with HIV
#8 - José Castillo-Mancilla, MD | University of Colorado-AMC, United States
Antiretroviral Exposure in Peripheral Blood Monuclear Cells and HIV DNA Decay During Primary Infection: A Randomized Clinical Trial With 3 Different Drug Regimens
#9 - Mattia Trunfio | University of Turin, Italy
Prediction of induction drug-drug interactions using an in vitro DMPK algorithm
#10 - Sandra Grañana Castillo | University Of Liverpool, United Kingdom
Panel Discussion on LA -
Panel Discussion
LA Controversies: Need for Oral Lead-In and How to Cover Tail of Injectable LA Regimens
Charles Flexner, MD
Johns Hopkins University School of Medicine, United States
Special Populations Including End Organ Failure: Focus on Long-Acting Cabotegravir and Rilpivirine
Parul Patel, Pharm.D.
ViiV Healthcare, United States
DDIs
Catia Marzolini, PharmD, PhD
University Hospital of Basel, University Hospital of Lausanne, Switzerland; University of Liverpool, United Kingdom
Day 3 - Wednesday, 22 September 2021
Pharmacological Considerations for Special Populations -
PrEP Benchmarks – Can They Cover All Populations – Pregnancy?
​​​​​​​Peter L. Anderson, PharmD
University of Colorado, Anschutz Medical Campus, United States
Immune Checkpoint Inhibitors in the Treatment of HBV
Debika Bhattacharya, MD MSc
University of California, Los Angeles, United States
Pharmacologically Focused to Optimize HIV Prevention for Transgender Women
Mackenzie L. Cottrell, PharmD
University of North Carolina, Chapel Hill, United States
Abstract-Driven Session -
Abstract Presentations
Tenofovir alafenamide concentrations are reduced by half in pregnant women living with HIV: data from the PANNA Network
#11 - Vera Bukkems | Radboudumc, the Netherlands
Tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following directly observed F/TDF dosing among transgender adolescents and young adults
#12 - Jenna Yager, PharmD | University of Colorado, United States
Pharmacogenetics of Tenofovir (Alafenamide or Disoproxil Fumarate Prodrugs) Renal Toxicity in HIV-positive Black South Africans
#13 - Somila Mateza | University Of Cape Town, South Africa
Using PBPK modelling to estimate lamivudine exposure in children with abnormal kidney function
14# - Tom Jacobs, PharmD | Radboudumc, the Netherlands
Charles Boucher Memorial Lecture -
Contribution of Pharmacology to HIV Cure
Angela DM Kashuba, BScPhm, PharmD, DABCP, FCP
University of North Carolina, Chapel Hill, United States
Overview
Image
Antiviral PK
In Memoriam: Dr. Charles Boucher

We are deeply saddened to share that Dr. Charles Boucher, a member of the Academic Advisory Board of the International Workshop on Clinical Pharmacology of HIV, Hepatitis and Other Antiviral Drugs 2021, has passed away after a courageous battle with cancer. Read our full memorial >

In Memoriam: Dr. John Gerber
Gerber_InMemoriam
John Gerber, MD
University of Colorado School of Medicine, United States

We are deeply saddened to hear that Dr. John Gerber has passed away. Dr. Gerber was an integral faculty member of the early Intl. Workshop on Clinical Pharmacology of HIV Drugs programs, which is now in its 22nd edition. His contributions to this program and the pharmacology field are tremendous and he will be missed.

Welcome

Understanding the clinical pharmacology of antiviral therapy is pivotal to designing optimal treatment and prevention strategies. The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs gathers leading experts to discuss all aspects of the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational and existing drugs, pharmacodynamics, drug dosing in special populations, post-marketing surveillance, and regulatory considerations.

Program Chairs 2021
General Information 
COVID-19 Update
Responding to the changing COVID-19 situation, the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021 will be held as a virtual meeting.

We are available to answer any questions or concerns that you may have about your participation at the International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021. For more information, please contact Ulrike Bilgram via ulrike@amededu.com.

To stay updated on developments about this workshop, make sure that you are signed up for our newsletter.
Unique Features
The International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs 2021 took place as a highly successful virtual workshop from 20-22 September. If you would like to watch the recordings from the conference, please register to enter the virtual workshop portal.

The workshop provided a platform for discussions on current topics fundamental to the optimal use of antiviral therapy including drug-drug interactions, pharmacokinetics of investigational agents and existing drugs, pharmacodynamics, drug dosing in special populations, postmarketing surveillance, and regulatory considerations.
Who Should Attend?
- Clinical pharmacologists;

- Pharmacists;

- Clinicians/ researchers;

- Industry representatives;

- Regulatory scientists;

- Government representatives;

- Post-graduate students; and

- Others involved in the clinical pharmacology of antiviral therapy.
Meeting Objectives
This meeting aims to:

- Gather experts involved in clinical pharmacology from different disciplines in an interactive workshop setting;

- Provide a platform for presentation and discussion of the latest developments in the field;

- Share information on ongoing pharmacological studies;

- Translate new data to treatment guidelines; and

- Stimulate discussion and consensus on best practices.
Learning Objectives
After participating in this activity, participants will be able to:

- Outline new developments in antiviral therapy;

- Identify treatment options for hepatitis-infected patients;

- Reflect on the role of pharmacogenomics in clinical management; and

- Describe the various pharmacological parameters of integrase inhibitors.
Practical Information 
Certificate of Attendance
A certificate of attendance will be sent to participants after they have successfully completed the program and post-meeting survey.
Language
The official language of the workshop is English.
Translation will not be provided.
Disclaimer
This workshop is intended for educational purposes only and aims to offer participants the opportunity to share information. The Organizing Secretariat of this event, Virology Education, cannot accept any liability for the scientific content of the sessions or for any claims which may result from the use of information or publications from this workshop. Virology Education disclaims all liability for injuries or losses of whatever nature incurred by individuals attending the workshop.
Liability and Insurance
By registering for the workshop, participants agree that the organizers do not accept responsibility for medical, travel, or personal insurance. Participants are advised to take out their own insurance policies.
Committees
Chairs 2021
Organizing Committee

The members of the Organizing Committee are a group of carefully selected experts and inspirational leaders in their respective fields. They meet frequently to discuss the scientific program of the workshop, identify interesting topics and candidate speakers, and review all submitted abstracts.

Scientific Committee

The members of Scientific Committee are hand-picked by the Organizing Committee and the conference secretariat based on their significant contributions and commitment to the field. They assist the Organizing Committee by providing them with suggestions for speakers and topics. In addition, members of the Scientific Committee participate in reviewing submitted abstracts, and play an active role during the workshop as moderators and/or chairs of sessions.

  • Peter Anderson, PharmD - University of Colorado Denver, United States
  • Tim Cressey, PhD - Chiang Mai University, Thailand
  • Rodolphe Garraffo, MD - Hopital Pasteur Nice, France
  • David Haas, MD - Vanderbilt University Medical Ctr, United States
  • Saye Khoo, MD - University of Liverpool, United Kingdom
  • Michael Kurowski, MD - Auguste-Victoria Hospital, Jerusalem
  • Mohammed Lamorde, MD - Infectious Diseases Institute, Uganda
  • Lawrence Lee, MBBS, PhD - National University of Singapore, Singapore
  • Gilles Peytavin, PharmD, PhD - Bichat-Cl. Bernard Hospital, France
  • Kellie Schoolar-Reynolds, PharmD - Food and Drug Administration, United States
  • Kimberly Struble, PharmD - Food and Drug Administration, United States
  • Stephen Taylor, MRCP, PhD - Birmingham Heartlands Hospital, United Kingdom
Academic Advisory Board

The members of the Academic Advisory Board (AAB) are former members of the OC and remain active the in planning of the program for the next year. Members of the current OC are selected from this group. 

  • David Back, PhD - University of Liverpool, United Kingdom
  • Terrence Blaschke, MD - Stanford University School of Medicine, United States
  • † Charles Boucher, PhD - Erasmus Medical Center, the Netherlands
  • David Burger, MD, PhD - Radboud University Medical Center, the Netherlands
  • Giovanni Di Perri, MD, PhD - University of Torino, Italy
  • Courtney Fletcher, PharmD - University of Nebraska Medical Center, United States
  • Charles Flexner, MD - Johns Hopkins University, United States
  • Angela Kashuba, PharmD - University of North Carolina at Chapel Hill, United States
  • Jürgen Rockstroh, MD - University of Bonn, Germany
  • Jonathan Schapiro, MD - Sheba Medical Centre, Israel
Industry Liaison Board

The Industry Liaison Board, consisting of leading medical scientists of the pharmaceutical industry, is asked to give input and suggestions that help the Organizing Committee in planning the workshop and providing support on topics of interest and innovative suggestions to optimize audience participation. The Industry Liaison Board assists the Organizing Committee by suggesting the most current and critical topics to bring the audience up-to-date on the most current research in the pharmaceutical industry in related disciplines.

  • Timonthy Eley - Arbutus
  • Yash Gandhi - BMS
  • Daria Hazuda - Merck
  • Thomas Kakuda - Alios BioPharma
  • Charles LaPorte - Janssen Biologics
  • Wei Liu - AbbVie
  • Anita Mathias - Gilead Sciences
  • Parul Patel - ViiV Healthcare
  • Manoli Vourvahis - Pfizer
Support
Platinum Level Sponsor
Silver Level Sponsors
Friend

Support Our Initiative
Financial backing helps us deliver an impactful meeting experience for the benefit of healthcare professionals, researchers, and community representatives involved in Clinical Pharmacology of HIV, Hepatitis, and other Antiviral Drugs.
 
This collaboration plays a vital role in both the organizational as well as scientific success of the program.
 
To show your commitment to the cause and get in touch with us for a tailored support package, please contact Ms. Goda Adomonis at goda.adomonis@amededu.com or call +31 6 23711504. 
 
Benefits of Support 
By supporting this program, we can offer the following advantages for your company.* Please contact us for the most recent support level benefits for this program.

  • Symposium opportunities
  • Non-commercial interviews with company representatives
  • Verbal acknowledgment during the program 
  • Discounted and complimentary registrations for your representatives
  • Company acknowledgment on digital meeting materials including but not limited to newsletters, flyers, the streaming platform, and our website
  • Company acknowledgment on printed meeting materials including but not limited to banners and the program book
  • Digital and printed advertising opportunities 
  • Social media shout-outs
  • Logo on the conference bag 

 
*Subject to the support level

Endorsers